Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | MMP1 | P03956 | 1/20 | 0.45 |
| ▸ | MMP3 | P08254 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13912231 | 0.98 | SMN1; SMN2 (0.58) | SMN1; SMN2PKMCYP3A4CYP2C19GAA | |
| SCHEMBL4546660 | 0.92 | SMN1; SMN2 (0.52) | SMN1; SMN2PKMCYP3A4CYP2C19GAA | |
| Fumaric Acid SCHEMBL2868406 | 0.88 | SMN1; SMN2 (0.44) | SMN1; SMN2PKMCYP3A4CYP2C19GAA | |
| SCHEMBL1106494 | 0.86 | SMN1; SMN2 (0.46) | SMN1; SMN2PKMCYP3A4CYP2C19GAA | |
| SCHEMBL15216104 | 0.84 | HSD17B10 (0.48) | SMN1; SMN2CYP3A4CYP2C19GAATSHR | |
| SCHEMBL762984 | 0.84 | SMN1; SMN2 (0.52) | SMN1; SMN2PKMCYP3A4CYP2C19GAA | |
| SCHEMBL2115037 | 0.84 | SMN1; SMN2 (0.52) | SMN1; SMN2PKMCYP3A4CYP2C19GAA | |
| SCHEMBL5778346 | 0.84 | SMN1; SMN2 (0.52) | SMN1; SMN2PKMCYP3A4CYP2C19GAA | |
| SCHEMBL3054776 | 0.84 | SMN1; SMN2 (0.52) | SMN1; SMN2PKMCYP3A4CYP2C19GAA | |
| SCHEMBL1911518 | 0.82 | ALOX15 (0.66) | SMN1; SMN2CYP3A4CYP2C19GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 890 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111819176-B | 4-azaindole compounds | 百时美施贵宝公司 | 2023-12-15 | — | — | CN | claimed |
| US-8888886-B1 | NBPT solutions for preparing urease inhibited urea fertilizers prepared from N-substituted morpholines | WHITEHURST ASSOCIATES, INC. | 2014-11-18 | — | — | US | claimed |
| US-8785443-B2 | Methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof | XENOPORT, INC. (US) | 2014-07-22 | — | — | US | claimed |
| US-20140057918-A1 | Methods of Use for Monomethyl Fumarate and Prodrugs Thereof | XENOPORT, INC. (US) | 2014-02-27 | — | — | US | claimed |
| WO-2014031901-A1 | METHODS OF USE FOR MONOMETHYL FUMARATE AND PRODRUGS THEREOF | XENOPORT, INC. (US) | 2014-02-27 | — | — | WO | claimed |
| WO-2010022177-A2 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2010-02-25 | — | — | WO | claimed |
| US-20100048651-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2010-02-25 | — | — | US | claimed |
| US-6906112-B1 | Radiation-curable, cyanoacrylate-containing compositions | HENKEL CORPORATION (US) | 2005-06-14 | — | — | US | claimed |
| US-6726795-B1 | COMPOSITION COMPRISING 2-CYANOACRYLATE MONOMER, METALLOCENE, PHOTOINITIATOR, SULFUR-CONTAINING COMPOUND, AND POLYMETHYL METHACRYLATE | Henkel IP & Holding GmbH (DE) | 2004-04-27 | — | — | US | claimed |
| US-20240246984-A1 | HETEROCYCLIC JAK INHIBITOR | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2024-07-25 | — | — | US | disclosed |
| US-20240240229-A1 | METHODS OF ADMINISTERING MONOMETHYL FUMARATE AND PRODRUGS THEREOF HAVING REDUCED SIDE EFFECTS | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2024-07-18 | — | — | US | disclosed |
| US-12037344-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037344-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2024-07-16 | — | — | US | disclosed |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20010025052-A1 | Novel nitric oxide-releasing amidine- and enamine-derived diazeniumdiolates, compositions and uses thereof and method of making same | HRABIE JOSEPH A (US) | 2001-09-27 | — | — | US | disclosed |
| US-6232336-B1 | HYPOTENSIVE AGENTS; NEUROTRANSMISSION; CYTOTOXICITY | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2001-05-15 | — | — | US | disclosed |
| EP-1073640-A1 | NAPHTHALENE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 2001-02-07 | — | — | EP | disclosed |
| EP-1000023-A2 | NOVEL NITRIC OXIDE-RELEASING AMIDINE- AND ENAMINE-DERIVED DIAZENIUMDIOLATES, COMPOSITIONS AND USES THEREOF AND METHOD OF MAKING SAME | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999054309-A1 | NAPHTHALENE DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-10-28 | — | — | WO | disclosed |
| WO-1999001427-A2 | NOVEL NITRIC OXIDE-RELEASING AMIDINE- AND ENAMINE-DERIVED DIAZENIUMDIOLATES, COMPOSITIONS AND USES THEREOF AND METHOD OF MAKING SAME | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH (US) | 1999-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | SMN1; SMN2 1811/4885PKM 2115/4885CYP3A4 4464/4885 |
| US-12037344-B2 | NLRP3 modulators | NLRP3, NLRP1, PYCARD | SMN1; SMN2 4781/4885PKM 1495/4885CYP3A4 562/4885 |
| US-20140057918-A1 | Methods of Use for Monomethyl Fumarate and Prodrugs Thereof | FH, FAH, DHFR | SMN1; SMN2 2493/4885PKM 384/4885CYP3A4 492/4885 |
| US-20240240229-A1 | METHODS OF ADMINISTERING MONOMETHYL FUMARATE AND PRODRUGS THEREOF HAVING REDUCED SIDE EFFECTS | GSTM1, GSTM2, GSTA1 | SMN1; SMN2 1538/4885PKM 679/4885CYP3A4 179/4885 |
| US-20240246984-A1 | HETEROCYCLIC JAK INHIBITOR | JAK2, JAK1, JAK3 | SMN1; SMN2 3234/4885PKM 1076/4885CYP3A4 1791/4885 |
| US-20100048651-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, MGMT, BHMT2 | SMN1; SMN2 2353/4885PKM 964/4885CYP3A4 78/4885 |
| US-20010025052-A1 | Novel nitric oxide-releasing amidine- and enamine-derived diazeniumdiolates, compositions and uses thereof and method of making same | NOS2, NOS1, NOS3 | SMN1; SMN2 1749/4885PKM 933/4885CYP3A4 669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.